Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Jinyouli (PEG-rhG-CSF) in Advanced Pancreatic Cancer
NCT04239001Unknown
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Feb 2020
- Primary completion
- Dec 2020
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Open-label, single-arm trial of pegylated granulocyte colony-stimulating factor in neutropenia, sponsored by CSPC Baike Biopharmaceutical. Primary endpoint: Incidence of degree 3-4 neutropenia in each cycle of chemotherapy. Status: unknown.
02
Drugs
pegylated granulocyte colony-stimulating factor
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT04239001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04239001.